\u65e5\u672c\u306f\u3001\u518d\u751f\u533b\u7642\u306e\u5206\u91ce\u3067\u6570\u5341\u5e74\u306b\u308f\u305f\u308a\u305d\u306e\u8a55\u4fa1\u3092\u7bc9\u3044\u3066\u304d\u307e\u3057\u305f\u3002\u305d\u306e\u8a55\u4fa1\u306e\u591a\u304f\u306f\u3001iPS\u7d30\u80de\uff08\u4eba\u5de5\u591a\u80fd\u6027\u5e79\u7d30\u80de\uff09\u306b\u95a2\u3059\u308b\u5148\u99c6\u7684\u306a\u7814\u7a76\u306b\u3088\u308b\u3082\u306e\u3067\u3059\u3002\u3057\u304b\u3057\u3001\u305d\u306e\u79d1\u5b66\u7684\u30ea\u30fc\u30c0\u30fc\u30b7\u30c3\u30d7\u3092\u6210\u529f\u3057\u305f\u30d3\u30b8\u30cd\u30b9\u3078\u3068\u7d50\u3073\u3064\u3051\u308b\u3053\u3068\u306b\u306f\u3001\u3088\u308a\u9577\u3044\u6642\u9593\u3092\u8981\u3057\u3066\u3044\u307e\u3059\u3002.<\/p>\n
\u4eac\u90fd\u3092\u62e0\u70b9\u3068\u3059\u308b\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u30b9\u30bf\u30fc\u30c8\u30a2\u30c3\u30d7\u306eRegeNephro\u306f\u3001\u305d\u306e\u72b6\u6cc1\u3092\u5909\u3048\u3064\u3064\u3042\u308b\u4f01\u696d\u306e\u3072\u3068\u3064\u304b\u3082\u3057\u308c\u307e\u305b\u3093\u3002.<\/p>\n
The company has raised \u00a51.22 billion through a J-KISS funding round, giving it fresh capital to move its kidney disease therapies closer to commercialization. The funding will support ongoing research, non-clinical studies, hiring, and preparations for a future Series C round. On paper, it is another biotech fundraising announcement. In reality, it reflects something much bigger that is happening across Japan’s life sciences industry.<\/p>\n
RegeNephro was established using research from Kyoto University’s Center for iPS Cell Research and Application (CiRA). Since its inception, the company has focused on developing treatments for kidney diseases where existing options remain limited.<\/p>\n
\u540c\u793e\u306e\u4e3b\u529b\u5019\u88dc\u85ac\u3067\u3042\u308bRN-014\u306f\u3001\u5e38\u67d3\u8272\u4f53\u512a\u6027\u591a\u767a\u6027\u56a2\u80de\u814e\uff08ADPKD\uff09\u3092\u5bfe\u8c61\u3068\u3057\u305f\u7b2c2a\u76f8\u81e8\u5e8a\u8a66\u9a13\u3092\u3059\u3067\u306b\u5b8c\u4e86\u3057\u3066\u3044\u307e\u3059\u3002 \u3082\u3046\u4e00\u3064\u306e\u30d7\u30ed\u30b0\u30e9\u30e0\u3067\u3042\u308bRN-032\u306f\u3001iPS\u7d30\u80de\u7531\u6765\u306e\u30cd\u30d5\u30ed\u30f3\u524d\u99c6\u7d30\u80de\u3092\u57fa\u76e4\u3068\u3057\u3066\u304a\u308a\u3001\u5358\u306b\u75be\u60a3\u306e\u9032\u884c\u3092\u9045\u3089\u305b\u308b\u3060\u3051\u3067\u306a\u304f\u3001\u518d\u751f\u533b\u7642\u3092\u901a\u3058\u3066\u814e\u6a5f\u80fd\u3092\u56de\u5fa9\u3055\u305b\u308b\u3053\u3068\u3092\u76ee\u6a19\u3068\u3057\u3066\u3044\u307e\u3059\u3002.<\/p>\n
\u3053\u306e\u3088\u3046\u306a\u6cbb\u7642\u6cd5\u3092\u958b\u767a\u3059\u308b\u306b\u306f\u3001\u591a\u984d\u306e\u8cbb\u7528\u3068\u9577\u3044\u6642\u9593\u304c\u304b\u304b\u308a\u307e\u3059\u3002\u81e8\u5e8a\u8a66\u9a13\u306f\u6570\u5e74\u306b\u3082\u53ca\u3073\u3001\u88fd\u9020\u57fa\u6e96\u306f\u53b3\u683c\u3067\u3042\u308a\u3001\u898f\u5236\u5f53\u5c40\u306e\u627f\u8a8d\u3092\u5f97\u308b\u306b\u306f\u5e83\u7bc4\u306a\u8a3c\u62e0\u304c\u6c42\u3081\u3089\u308c\u307e\u3059\u3002\u305d\u306e\u305f\u3081\u3001\u8cc7\u91d1\u8abf\u9054\u3078\u306e\u30a2\u30af\u30bb\u30b9\u306f\u3001\u79d1\u5b66\u7684\u306a\u30d6\u30ec\u30fc\u30af\u30b9\u30eb\u30fc\u3068\u540c\u3058\u304f\u3089\u3044\u91cd\u8981\u3067\u3059\u3002\u8cc7\u91d1\u304c\u306a\u3051\u308c\u3070\u3001\u6709\u671b\u306a\u7814\u7a76\u3067\u3042\u3063\u3066\u3082\u3001\u524d\u9032\u3059\u308b\u306e\u304c\u56f0\u96e3\u306b\u306a\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002.<\/p>\n
\u4eca\u56de\u306e\u6295\u8cc7\u306b\u3088\u308a\u3001 RegeNephro<\/a> \u6b21\u56de\u306e\u8cc7\u91d1\u8abf\u9054\u6bb5\u968e\u306b\u5148\u7acb\u3061\u3001\u81ea\u793e\u306e\u5730\u4f4d\u3092\u5f37\u5316\u3057\u3064\u3064\u3001\u958b\u767a\u3092\u7d99\u7d9a\u3059\u308b\u305f\u3081\u306e\u4f59\u5730\u304c\u3055\u3089\u306b\u5e83\u304c\u308a\u307e\u3059\u3002.<\/p>\n \u65e5\u672c\u306b\u306f\u3001\u79d1\u5b66\u5206\u91ce\u306e\u512a\u308c\u305f\u4eba\u6750\u304c\u5e38\u306b\u8c4a\u5bcc\u306b\u5b58\u5728\u3057\u3066\u304d\u307e\u3057\u305f\u3002\u5927\u5b66\u3084\u7814\u7a76\u6a5f\u95a2\u306f\u3001\u5e79\u7d30\u80de\u79d1\u5b66\u3084\u518d\u751f\u533b\u7642\u306e\u5206\u91ce\u306b\u304a\u3044\u3066\u3001\u4e00\u8cab\u3057\u3066\u4e16\u754c\u30c8\u30c3\u30d7\u30ec\u30d9\u30eb\u306e\u767a\u898b\u3092\u751f\u307f\u51fa\u3057\u3066\u304d\u307e\u3057\u305f\u3002\u8ab2\u984c\u306f\u3001\u5e38\u306b\u305d\u308c\u3089\u306e\u767a\u898b\u3092\u5927\u898f\u6a21\u306b\u5546\u7528\u5316\u3059\u308b\u3053\u3068\u306b\u3042\u308a\u307e\u3057\u305f\u3002.<\/p>\n \u305d\u306e\u72b6\u6cc1\u306f\u5f90\u3005\u306b\u5909\u308f\u308a\u3064\u3064\u3042\u308a\u307e\u3059\u3002.<\/p>\n J-KISS\u306e\u3088\u3046\u306a\u8cc7\u91d1\u8abf\u9054\u30e2\u30c7\u30eb\u306b\u3088\u308a\u3001\u30c7\u30a3\u30fc\u30d7\u30c6\u30c3\u30af\u7cfb\u30b9\u30bf\u30fc\u30c8\u30a2\u30c3\u30d7\u306f\u3001\u4f01\u696d\u4fa1\u5024\u3092\u76f4\u3061\u306b\u78ba\u5b9a\u3055\u305b\u308b\u3053\u3068\u306a\u304f\u3001\u8cc7\u91d1\u3092\u8abf\u9054\u3057\u3084\u3059\u304f\u306a\u3063\u3066\u3044\u307e\u3059\u3002\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u306e\u5275\u696d\u8005\u306e\u7686\u3055\u3093\u306b\u3068\u3063\u3066\u3001\u7814\u7a76\u306f\u4e88\u6e2c\u53ef\u80fd\u306a\u30b9\u30b1\u30b8\u30e5\u30fc\u30eb\u901a\u308a\u306b\u9032\u3080\u3053\u3068\u304c\u3081\u3063\u305f\u306b\u306a\u3044\u305f\u3081\u3001\u3053\u3046\u3057\u305f\u67d4\u8edf\u6027\u306f\u91cd\u8981\u3067\u3059\u3002\u307e\u305f\u3001\u6295\u8cc7\u5bb6\u306b\u3068\u3063\u3066\u3082\u3001\u4f01\u696d\u306e\u6210\u9577\u904e\u7a0b\u306e\u3088\u308a\u65e9\u3044\u6bb5\u968e\u3067\u652f\u63f4\u3092\u884c\u3046\u6a5f\u4f1a\u304c\u5f97\u3089\u308c\u307e\u3059\u3002.<\/p>\n The rise of funding mechanisms designed specifically for startups shows that Japan’s investment ecosystem is evolving alongside its innovation ecosystem. That is good news not only for biotechnology companies but also for researchers looking to bring academic discoveries into the market.<\/p>\n RegeNephro\u306f\u30d8\u30eb\u30b9\u30b1\u30a2\u5206\u91ce\u3067\u4e8b\u696d\u3092\u5c55\u958b\u3057\u3066\u3044\u307e\u3059\u304c\u3001\u4eca\u56de\u306e\u6295\u8cc7\u306e\u5f71\u97ff\u306f\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u5206\u91ce\u3092\u306f\u308b\u304b\u306b\u8d85\u3048\u3066\u5e83\u304c\u3063\u3066\u3044\u307e\u3059\u3002.<\/p>\n \u73fe\u4ee3\u306e\u518d\u751f\u533b\u7642\u306f\u3001\u5b9f\u9a13\u5ba4\u3067\u306e\u7814\u7a76\u3060\u3051\u306b\u3068\u3069\u307e\u308a\u307e\u305b\u3093\u3002AI\u306f\u751f\u7269\u5b66\u7684\u30c7\u30fc\u30bf\u306e\u5206\u6790\u306b\u6d3b\u7528\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u81ea\u52d5\u5316\u306b\u3088\u308a\u3001\u5b9f\u9a13\u5ba4\u306e\u52b9\u7387\u304c\u5411\u4e0a\u3057\u3066\u3044\u307e\u3059\u3002\u7d30\u80de\u88fd\u9020\u306b\u304a\u3044\u3066\u30ed\u30dc\u30c3\u30c8\u5de5\u5b66\u304c\u679c\u305f\u3059\u5f79\u5272\u306f\u307e\u3059\u307e\u3059\u5927\u304d\u304f\u306a\u3063\u3066\u304a\u308a\u3001\u4e00\u65b9\u3067\u30af\u30e9\u30a6\u30c9\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u7814\u7a76\u8005\u304c\u81a8\u5927\u306a\u91cf\u306e\u79d1\u5b66\u60c5\u5831\u3092\u7ba1\u7406\u3059\u308b\u306e\u3092\u652f\u63f4\u3057\u3066\u3044\u307e\u3059\u3002.<\/p>\n \u518d\u751f\u533b\u7642\u4f01\u696d\u306e\u62e1\u5927\u306b\u4f34\u3044\u3001\u3053\u3046\u3057\u305f\u652f\u63f4\u6280\u8853\u3078\u306e\u9700\u8981\u3082\u540c\u69d8\u306b\u9ad8\u307e\u308b\u3068\u898b\u8fbc\u307e\u308c\u307e\u3059\u3002.<\/p>\n For Japan’s technology sector, this creates opportunities that go beyond healthcare alone. Companies building software for research laboratories, manufacturers producing precision equipment, cloud service providers, and AI startups could all find themselves serving a rapidly growing customer base.<\/p>\n \u3053\u3046\u3057\u305f\u696d\u754c\u6a2a\u65ad\u7684\u306a\u6210\u9577\u306f\u3001\u307e\u3059\u307e\u3059\u4e00\u822c\u7684\u306b\u306a\u3063\u3066\u304d\u3066\u3044\u307e\u3059\u3002\u3042\u308b\u5206\u91ce\u3067\u306e\u9032\u5c55\u304c\u3001\u3057\u3070\u3057\u3070\u4ed6\u306e\u3044\u304f\u3064\u304b\u306e\u5206\u91ce\u306b\u307e\u305f\u304c\u3063\u3066\u6a5f\u4f1a\u3092\u751f\u307f\u51fa\u3059\u306e\u3067\u3059\u3002.<\/p>\n \u3053\u306e\u8cc7\u91d1\u8abf\u9054\u30e9\u30a6\u30f3\u30c9\u3092\u6ce8\u8996\u3057\u3066\u3044\u308b\u306e\u306f\u3001RegeNephro\u3060\u3051\u3067\u306f\u3042\u308a\u307e\u305b\u3093\u3002.<\/p>\n \u5927\u624b\u88fd\u85ac\u4f1a\u793e\u306f\u3001\u81ea\u793e\u306e\u30d1\u30a4\u30d7\u30e9\u30a4\u30f3\u3092\u5f37\u5316\u3067\u304d\u308b\u9769\u65b0\u7684\u306a\u6cbb\u7642\u6cd5\u3092\u5e38\u306b\u6a21\u7d22\u3057\u3066\u3044\u307e\u3059\u3002\u3059\u3079\u3066\u306e\u6cbb\u7642\u6cd5\u3092\u81ea\u793e\u5185\u3067\u958b\u767a\u3059\u308b\u306e\u3067\u306f\u306a\u304f\u3001\u591a\u304f\u306e\u4f01\u696d\u306f\u73fe\u5728\u3001\u3059\u3067\u306b\u8457\u3057\u3044\u79d1\u5b66\u7684\u9032\u6b69\u3092\u9042\u3052\u3066\u3044\u308b\u30b9\u30bf\u30fc\u30c8\u30a2\u30c3\u30d7\u4f01\u696d\u3068\u63d0\u643a\u3057\u305f\u308a\u3001\u305d\u306e\u6280\u8853\u306e\u30e9\u30a4\u30bb\u30f3\u30b9\u3092\u53d6\u5f97\u3057\u305f\u308a\u3059\u308b\u3053\u3068\u3092\u597d\u3093\u3067\u3044\u307e\u3059\u3002.<\/p>\n If RegeNephro continues to advance its clinical programs, it could become an attractive partner not only in Japan but also overseas. The company’s ambitions already extend beyond the domestic market, with global commercialization remaining an important long-term objective.<\/p>\n \u305d\u306e\u5f71\u97ff\u306f\u3001\u59d4\u8a17\u7814\u7a76\u6a5f\u95a2\u3001\u81e8\u5e8a\u8a66\u9a13\u5b9f\u65bd\u6a5f\u95a2\u3001\u898f\u5236\u95a2\u9023\u30b3\u30f3\u30b5\u30eb\u30bf\u30f3\u30c8\u3001\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u6a5f\u5668\u30e1\u30fc\u30ab\u30fc\u3001\u304a\u3088\u3073\u7d30\u80de\u6cbb\u7642\u88fd\u54c1\u306e\u88fd\u9020\u306b\u643a\u308f\u308b\u4f01\u696d\u306b\u3082\u53ca\u3093\u3067\u3044\u307e\u3059\u3002\u518d\u751f\u533b\u7642\u30d7\u30ed\u30b0\u30e9\u30e0\u304c\u958b\u767a\u306e\u6700\u7d42\u6bb5\u968e\u306b\u9032\u3080\u306b\u3064\u308c\u3001\u5c02\u9580\u7684\u306a\u30b5\u30fc\u30d3\u30b9\u306b\u5bfe\u3059\u308b\u9700\u8981\u306f\u3055\u3089\u306b\u9ad8\u307e\u308b\u3068\u4e88\u60f3\u3055\u308c\u307e\u3059\u3002.<\/p>\n \u6cbb\u7642\u6cd5\u304c\u5546\u696d\u751f\u7523\u306e\u6bb5\u968e\u306b\u8fd1\u3065\u304f\u306b\u3064\u308c\u3001\u5b9f\u9a13\u5ba4\u81ea\u52d5\u5316\u3001\u54c1\u8cea\u7ba1\u7406\u30bd\u30d5\u30c8\u30a6\u30a7\u30a2\u3001\u304a\u3088\u3073\u5148\u9032\u7684\u306a\u88fd\u9020\u30b7\u30b9\u30c6\u30e0\u3092\u63d0\u4f9b\u3059\u308b\u4f01\u696d\u3082\u6069\u6075\u3092\u53d7\u3051\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002.<\/p>\n 1\u56de\u306e\u8cc7\u91d1\u8abf\u9054\u30e9\u30a6\u30f3\u30c9\u306e\u6210\u529f\u3060\u3051\u3067\u3001\u696d\u754c\u5168\u4f53\u3092\u5b9a\u7fa9\u3059\u308b\u3053\u3068\u306f\u3067\u304d\u307e\u305b\u3093\u3002\u3068\u306f\u3044\u3048\u3001\u3053\u306e\u3088\u3046\u306a\u767a\u8868\u306f\u307e\u3059\u307e\u3059\u591a\u304f\u306a\u3063\u3066\u304d\u3066\u304a\u308a\u3001\u305d\u308c\u306f\u6295\u8cc7\u5bb6\u306e\u5fc3\u7406\u3092\u7269\u8a9e\u3063\u3066\u3044\u308b\u3068\u8a00\u3048\u307e\u3059\u3002.<\/p>\n \u30c7\u30a3\u30fc\u30d7\u30c6\u30c3\u30af\u4f01\u696d\u306f\u3001\u53ce\u76ca\u304c\u5f97\u3089\u308c\u308b\u307e\u3067\u306b\u6570\u5e74\u3092\u8981\u3059\u308b\u3053\u3068\u304c\u591a\u3044\u305f\u3081\u3001\u5f93\u6765\u304b\u3089\u8cc7\u91d1\u8abf\u9054\u306b\u8ab2\u984c\u3092\u62b1\u3048\u3066\u304d\u307e\u3057\u305f\u3002\u7279\u306b\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u5206\u91ce\u306f\u53b3\u3057\u3044\u72b6\u6cc1\u306b\u3042\u308a\u307e\u3059\u3002\u88fd\u54c1\u304c\u60a3\u8005\u306e\u624b\u5143\u306b\u5c4a\u304f\u307e\u3067\u306b\u306f\u3001\u9577\u3044\u7814\u7a76\u671f\u9593\u3001\u53b3\u683c\u306a\u898f\u5236\u5f53\u5c40\u306e\u76e3\u7763\u3001\u305d\u3057\u3066\u591a\u984d\u306e\u6295\u8cc7\u304c\u5fc5\u8981\u3068\u306a\u308a\u307e\u3059\u3002.<\/p>\n \u6295\u8cc7\u5bb6\u305f\u3061\u306f\u3001\u3053\u3046\u3057\u305f\u73fe\u5b9f\u3092\u53d7\u3051\u5165\u308c\u308b\u59ff\u52e2\u3092\u307e\u3059\u307e\u3059\u5f37\u3081\u3066\u3044\u308b\u3088\u3046\u3067\u3059\u3002\u77ed\u671f\u7684\u306a\u5229\u76ca\u3092\u8ffd\u3044\u6c42\u3081\u308b\u306e\u3067\u306f\u306a\u304f\u3001\u591a\u304f\u306e\u6295\u8cc7\u5bb6\u304c\u3001\u4eca\u5f8c10\u5e74\u9593\u3067\u533b\u7642\u306e\u3042\u308a\u65b9\u3092\u4e00\u5909\u3055\u305b\u308b\u53ef\u80fd\u6027\u3092\u79d8\u3081\u305f\u6280\u8853\u306b\u6295\u8cc7\u3057\u3066\u3044\u307e\u3059\u3002.<\/p>\n \u3053\u3046\u3057\u305f\u5909\u5316\u306b\u3088\u308a\u3001\u3088\u308a\u591a\u304f\u306e\u8d77\u696d\u5bb6\u304c\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u95a2\u9023\u306e\u30d9\u30f3\u30c1\u30e3\u30fc\u3092\u7acb\u3061\u4e0a\u3052\u308b\u3088\u3046\u4fc3\u3055\u308c\u308b\u4e00\u65b9\u3067\u3001\u65e2\u5b58\u306e\u30b9\u30bf\u30fc\u30c8\u30a2\u30c3\u30d7\u4f01\u696d\u306b\u3068\u3063\u3066\u3082\u3001\u6210\u9577\u904e\u7a0b\u306b\u304a\u3044\u3066\u8cc7\u91d1\u8abf\u9054\u304c\u5f15\u304d\u7d9a\u304d\u53ef\u80fd\u3067\u3042\u308b\u3068\u3044\u3046\u78ba\u4fe1\u3092\u6df1\u3081\u308b\u3053\u3068\u306b\u306a\u308b\u3067\u3057\u3087\u3046\u3002.<\/p>\n The significance of RegeNephro’s latest funding extends beyond a single company.<\/p>\n \u6210\u529f\u3092\u53ce\u3081\u305f\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u306e\u30b9\u30bf\u30fc\u30c8\u30a2\u30c3\u30d7\u306f\u3001\u3044\u305a\u308c\u3082\u5468\u8fba\u306e\u30a8\u30b3\u30b7\u30b9\u30c6\u30e0\u3092\u5f37\u5316\u3057\u307e\u3059\u3002\u6295\u8cc7\u304c\u5897\u3048\u308c\u3070\u3001\u96c7\u7528\u3082\u5897\u3048\u307e\u3059\u3002\u96c7\u7528\u304c\u5897\u3048\u308c\u3070\u3001\u7814\u7a76\u30c1\u30fc\u30e0\u3082\u3088\u308a\u5f37\u529b\u306b\u306a\u308a\u307e\u3059\u3002\u5546\u696d\u5316\u304c\u6210\u529f\u3059\u308c\u3070\u3001\u3055\u3089\u306a\u308b\u6295\u8cc7\u5bb6\u3092\u60f9\u304d\u3064\u3051\u3001\u305d\u308c\u304c\u6b21\u4e16\u4ee3\u306e\u30b9\u30bf\u30fc\u30c8\u30a2\u30c3\u30d7\u3092\u652f\u3048\u308b\u3053\u3068\u306b\u306a\u308a\u307e\u3059\u3002.<\/p>\n \u3053\u308c\u306f\u3001\u65e5\u672c\u304c\u9577\u5e74\u306b\u308f\u305f\u308a\u69cb\u7bc9\u306b\u52aa\u3081\u3066\u304d\u305f\u4ed5\u7d44\u307f\u3067\u3059\u3002.<\/p>\n There is also an international angle. As Japanese biotech companies continue developing therapies that address global healthcare challenges, they have the opportunity to attract overseas partnerships, licensing agreements, and strategic investments. That not only strengthens individual companies but also raises Japan’s profile as a destination for life sciences innovation.<\/p>\n RegeNephro still has a long road ahead. Clinical development is rarely straightforward, and bringing regenerative therapies to market is never guaranteed. Even so, this funding round reflects growing confidence in both the company’s technology and the broader direction of Japan’s regenerative medicine sector.<\/p>\n If more startups can successfully make the journey from university research to commercial success, Japan’s leadership in regenerative medicine may soon be measured not only by scientific discoveries, but also by the businesses built around them.<\/p>","protected":false},"excerpt":{"rendered":" Japan has spent decades building its reputation in regenerative medicine. Much of that recognition comes from its pioneering work in induced pluripotent stem (iPS) cells. What has taken longer is turning that scientific leadership into successful businesses. Kyoto-based biotech startup RegeNephro may be one of the companies beginning to change that story. The company has raised \u00a51.22 billion through a J-KISS funding round, giving it fresh capital to move its kidney disease therapies closer to commercialization. The funding will support ongoing research, non-clinical studies, hiring, and preparations for a future Series C round. On paper, it is another biotech fundraising announcement. In reality, it reflects something much bigger that is […]<\/p>\n","protected":false},"author":7,"featured_media":35524,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"wprm-recipe-roundup-name":"","wprm-recipe-roundup-description":"","postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"footnotes":""},"categories":[1,89,198,8098],"tags":[13886,2550,13887,105,106,13885,592],"ppma_author":[572],"class_list":["post-35556","post","type-post","status-publish","format-standard","has-post-thumbnail","category-fintech","category-health-tech","category-investments","category-news-articles","tag-biotechnology-equipment-manufacturers","tag-clinical-development","tag-induced-pluripotent-stem","tag-itbusinesstoday","tag-news","tag-regenephro","tag-regenerative-medicine"],"yoast_head":"\n\u3053\u3061\u3089\u3082\u304a\u8aad\u307f\u304f\u3060\u3055\u3044\uff1a \u30c7\u30b8\u30bf\u30eb\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u3068\u6f22\u65b9\u533b\u5b66\u304c\u3001\u65e5\u672c\u306e\u533b\u7642\u696d\u754c\u3092\u3069\u306e\u3088\u3046\u306b\u5909\u9769\u3057\u3046\u308b\u304b<\/a><\/strong><\/h4>\n
\u7814\u7a76\u5ba4\u3067\u306e\u7814\u7a76\u304b\u3089\u5546\u696d\u7684\u306a\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u3078<\/h3>\n
\u65e5\u672c\u306e\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u7523\u696d\u306b\u3068\u3063\u3066\u306e\u610f\u5473<\/h3>\n
\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u5206\u91ce\u306e\u5404\u4f01\u696d\u304c\u3069\u306e\u3088\u3046\u306a\u6069\u6075\u3092\u53d7\u3051\u3089\u308c\u308b\u304b<\/h3>\n
\u65e5\u672c\u306e\u30c7\u30a3\u30fc\u30d7\u30c6\u30c3\u30af\u306b\u5bfe\u3059\u308b\u6295\u8cc7\u5bb6\u306e\u4fe1\u983c\u304c\u9ad8\u307e\u3063\u3066\u3044\u307e\u3059<\/h3>\n
The Bigger Picture for Japan’s Innovation Economy<\/h3>\n